PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20102700-0	2010	Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4.	Metformin	0-9	fatty acid binding protein 4	Homo sapiens	98-126	
20102700-6	2010	Metformin promoted the expression of carnitine palmitoyltransferase I (CPT-1), while reduced the expression of fatty acid-binding protein 4 (FABP4) which was involved in PA-induced lipid accumulation.	Metformin	0-9	fatty acid binding protein 4	Homo sapiens	111-139	
20102700-6	2010	Metformin promoted the expression of carnitine palmitoyltransferase I (CPT-1), while reduced the expression of fatty acid-binding protein 4 (FABP4) which was involved in PA-induced lipid accumulation.	Metformin	0-9	fatty acid binding protein 4	Homo sapiens	141-146	
20102700-7	2010	Quantitative real-time PCR showed that metformin regulates FABP4 expression at the transcriptional level.	Metformin	39-48	fatty acid binding protein 4	Homo sapiens	59-64	
20102700-11	2010	Metformin reduced FABP4 expression by promoting FOXO1 nuclear exclusion and subsequently inhibiting its activity.	Metformin	0-9	fatty acid binding protein 4	Homo sapiens	18-23	
20102700-12	2010	CONCLUSIONS: Taken together, these results suggest that metformin reduces lipid accumulation in macrophages by repressing FOXO1-mediated FABP4 transcription.	Metformin	56-65	fatty acid binding protein 4	Homo sapiens	137-142	
34163481-3	2021	The mechanisms by which metformin regulates the function of macrophages include AMPK, AMPK independent targets, NF-kappaB, ABCG5/8, Sirt1, FOXO1/FABP4 and HMGB1.	Metformin	24-33	fatty acid binding protein 4	Homo sapiens	145-150	
30575815-6	2019	In vitro, glucose, insulin, VEGFA and hypoxia upregulated endothelial FABP4, which was reversed by metformin through mTOR pathway inhibition.	Metformin	99-108	fatty acid binding protein 4	Homo sapiens	70-75	
29351188-8	2018	Metformin promoted HUVEC migration and inhibited apoptosis via upregulation of vascular endothelial growth factor (VEGF) receptors (VEGFR1/R2), fatty acid binding protein 4 (FABP4), ERK/mitogen-activated protein kinase signaling, chemokine ligand 8, lymphocyte antigen 96, Rho kinase 1 (ROCK1), matrix metalloproteinase 16 (MMP16) and tissue factor inhibitor-2 under hyperglycemia-chemical hypoxia.	Metformin	0-9	fatty acid binding protein 4	Homo sapiens	144-172	
29351188-8	2018	Metformin promoted HUVEC migration and inhibited apoptosis via upregulation of vascular endothelial growth factor (VEGF) receptors (VEGFR1/R2), fatty acid binding protein 4 (FABP4), ERK/mitogen-activated protein kinase signaling, chemokine ligand 8, lymphocyte antigen 96, Rho kinase 1 (ROCK1), matrix metalloproteinase 16 (MMP16) and tissue factor inhibitor-2 under hyperglycemia-chemical hypoxia.	Metformin	0-9	fatty acid binding protein 4	Homo sapiens	174-179	
29351188-9	2018	Therefore, metformin"s dual effect in hyperglycemia-chemical hypoxia is mediated by direct effect on VEGFR1/R2 leading to activation of cell migration through MMP16 and ROCK1 upregulation, and inhibition of apoptosis by increase in phospho-ERK1/2 and FABP4, components of VEGF signaling cascades.	Metformin	11-20	fatty acid binding protein 4	Homo sapiens	251-256	
25948182-7	2015	RESULTS: The metformin lowered the OD value, and the expression levels of both adipogenic genes C/EBPalpha and FABP4 were lower than those of controls, while the expression level of PPARgamma mRNA was not significantly changed, the apoptosis rate of leukemia cells co-caltured with metformin-treated adipocytes was higher than that of co-cultured cells without metformin treatment.	Metformin	13-22	fatty acid binding protein 4	Homo sapiens	111-116	
23480783-0	2013	Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies.	Metformin	122-131	fatty acid binding protein 4	Homo sapiens	5-33